Search

Displaying results 1201 - 1210 of 5383 in total
  1. Drug

    Yohimbine

    go.drugbank.com/drugs/DB01392
    ApprovedInvestigationalVet approvedWithdrawn

    A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of impotence. It is also alleged to be an aphrodisiac.

  2. Drug

    Finafloxacin

    go.drugbank.com/drugs/DB09047
    ApprovedWithdrawn

    Finafloxacin is marketed by Novartis under the brand Xtoro™, and was approved by the FDA in December 2014. … Finafloxacin is a fluoroquinolone antibiotic indicated in the treatment of acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus.

  3. Drug

    Acamprosate

    go.drugbank.com/drugs/DB00659
    ApprovedInvestigational

    Alcohol use disorder is responsible for a large worldwide burden of morbidity, premature mortality, and economic consequences resulting from accidents, violence, incarceration, decreased productivity, … It was first approved by the FDA in 2004 and initially marketed by Forest Laboratories.[L31783]

  4. Drug

    Luspatercept

    go.drugbank.com/drugs/DB12281
    ApprovedInvestigational

    [A187829,L42455] It was first approved for use in the United States in November 2019 under the brand name Reblozyl® for the treatment of anemia in patients with beta thalassemia who require regular blood

  5. Drug

    Oxybuprocaine

    go.drugbank.com/drugs/DB00892
    ApprovedInvestigational

    Oxybuprocaine (also known as Benoxinate) is a local anesthetic, which is used especially in ophthalmology and otolaryngology. Oxybuprocaine binds to sodium channels and reversibly stabilizes the neuronal membrane which decreases its perm...

    Mixtures: Fluorescein Sodium & Benoxinate Hydrochloride Ophthalmic Solution, USPCategories: Anesthetics for Topical Use
  6. Drug

    Gallium Ga-68 gozetotide

    go.drugbank.com/drugs/DB16019
    ApprovedInvestigational

    [L43542] In December of the same year, the drug was fully authorized by the EMA.[L44682] In Octer 2022, Ga-68 PSMA-11 was approved by Health Canada for diagnostic use in men with prostate cancer. … In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended Ga-68 gozetotide be granted marketing authorization for the diagnosis of prostate cancer.

  7. Drug

    Etofamide

    go.drugbank.com/drugs/DB13258
    Approved

    Etofamide, under the brand name Kitnos, was marketed in Brazil by Pfizer but has been discontinued [L5617].

  8. Drug

    Lasmiditan

    go.drugbank.com/drugs/DB11732
    ApprovedInvestigational

    suitable for use in patients with pre-existing cardiovascular disorders. … [sumatriptan]) have seen preferential use in the acute treatment of migraines due to their relatively favourable efficacy and safety.

  9. Drug

    Fluclorolone acetonide

    go.drugbank.com/drugs/DB08973
    ApprovedWithdrawn

    Fluclorolone acetonide (INN) or flucloronide (USAN) is a topical corticosteroid. It is marketed under the brand names Cutanit and Topicon.

  10. Drug

    Voxelotor

    go.drugbank.com/drugs/DB14975
    Approved

    The EMA approved the use of voxelotor for the treatment of hemolytic anemia associated with sickle cell disease in February 2022.[L41419,L41424] … [L10403] It was developed by Global Blood Therapeutics, Inc.